

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (ZZ-107)

OLENDALIZUMAB

PRONUNCIATION

oh len" da liz' ue mab

THERAPEUTIC CLAIM

Treatment of inflammatory conditions including systemic lupus erythematosus (SLE) and/ or lupus nephritis (LN), acute graft versus host disease involving the gastrointestinal tract, and antiphospholipid syndrome

CHEMICAL NAMES

1. Immunoglobulin, anti-(human complement C5a) (human-*Mus musculus* ALXN1007 heavy chain), disulfide with human-*Mus musculus* ALXN1007 κ -chain, dimer

STRUCTURAL FORMULA

Heavy chain

QVQLVQSGAE	VKKPGASVKV	SCKASGYTFT	DYSMDWVRQA	PGQGLEWMGA	50
IHLNTGYTNY	NQKFKGRVTM	TRDTSTSTVY	MELSSLRSED	TAVYYCARGF	100
YDGYSPMDYW	GQGTTVTSS	ASTKGPSVFP	LAPCSRSTSE	STAALGCLVK	150
DYFPEPVTVS	WNSGALTSGV	HTFPAVLQSS	GLYSLSSVVT	VPSNFGTQT	200
YTCNVDHKPS	NTKVDKTVER	KCCVECPPCP	APPVAGPSVF	LFPPKPKDTL	250
MISRTPEVTC	VVVDVSGQEDP	EVQFNWYVDG	VEVHNAKTKP	REEQFNSTYR	300
VVSVLTVLHQ	DWLNGKEYKC	KVSNKGLPSS	IEKTI SKAKG	QPREPQVYTL	350
PPSQEEMTKN	QVSLTCLVKG	FYPSDIAVEW	ESNGQPENNY	KTTTPVLDS	400
GSFFLYSRLT	VDKSRWQEGN	VFSCVMHEA	LHNHYTQKSL	SLSLGK	446

Light chain

DIQMTQSPSS	LSASVGDRVT	ITCRASESVD	SYGNSFMHWY	QQKPGKAPKL	50'
LIYRASNLES	GVPSRFGSG	SGTDFLTIS	SLQPEDFATY	YCQQSNEDPY	100'
TFGGGTKVEI	KRTVAAPSVF	IFPPSDEQLK	SGTASVVCLL	NNFYPREAKV	150'
QWKVDNALQS	GNSQESVTEQ	DSKSTYSLS	STLTLSKADY	EKHKVYACEV	200'
THQGLSSPVT	KSFNRGEC				218'

Disulfide bridges location

22-96	22"-96"	23'-92'	23"-92"	134-218'	134"-218"
138'-198'	138"-198"	147-203	147"-203"	222-222"	223-223"
226-226"	229-229"	260-320	260"-320"	366-424	366"-424"

Glycosylation sites (N)

Asn-296 Asn-296'

MOLECULAR FORMULA

$C_{6538}H_{10060}N_{1716}O_{2132}S_{56}$

MOLECULAR WEIGHT

148.6 kDa (peptide)

TRADEMARK

None as yet

SPONSOR

Alexion Pharmaceuticals

CODE DESIGNATIONS

ALXN1007 antibody

CAS REGISTRY NUMBER 1337966-73-0

UNII 4971UQC7F3

WHO NUMBER 10037

gbk